if Anavex simply maintains the status quo of the single current 25 patient trial that Australia is subsidizing.
Is Australia subsidizing?
Beyond tax credits available to any biotech company that sets up shop there? If not, maybe the expectations (from others) that Australia is going to have a role going forward should be tempered.
Market Data 
Markets 
AI
